Indirect Coombs Test (ICT Titre) – Overview

What is the Indirect Coombs Test (ICT Titre)?

The Indirect Coombs Test (ICT), also known as the Indirect Antiglobulin Test (IAT), detects antibodies against red blood cells (RBCs) in the serum. It is primarily used in blood transfusion compatibility testing, pregnancy-related antibody screening, and hemolytic disease of the newborn (HDN) risk assessment.

📌 A high ICT titre indicates a significant level of antibodies that could lead to transfusion reactions or fetal complications in pregnancy.

---

1. Why is the Indirect Coombs Test Done?

✅ In Blood Transfusion:

• To detect unexpected antibodies in the recipient’s serum before a transfusion.
• Prevents hemolytic transfusion reactions (antibody-mediated destruction of transfused RBCs).

✅ In Pregnancy (Antenatal Screening):

• To screen for maternal antibodies against fetal RBC antigens, especially in Rh-negative mothers carrying an Rh-positive baby.
• Prevents Hemolytic Disease of the Newborn (HDN).
• Determines if the mother requires anti-D immunoglobulin (Rhogam) prophylaxis.

✅ In Autoimmune Hemolytic Anemia (AIHA):

• Identifies circulating RBC autoantibodies that may cause hemolysis.

---

2. Test Procedure

📌 Sample Collection:

• Blood sample (serum/plasma) collected via venipuncture.
• No fasting required.

📌 Test Methodology:

• Patient’s serum is mixed with test RBCs carrying known antigens.
• After washing, Coombs reagent (anti-human globulin) is added.
• If antibodies are present, RBC agglutination (clumping) occurs, indicating a positive ICT.

📌 Titre Measurement:

• Serial dilutions of the patient’s serum are tested to determine the highest dilution (titre) at which agglutination still occurs.
• Higher titres indicate stronger antibody presence and potential clinical significance.

---

3. Interpretation of ICT Titre Results

📌 For pregnant women with high ICT titres, fetal monitoring and potential intrauterine transfusions may be required.

---

4. Clinical Applications & Conditions

🚩 Blood Transfusion Compatibility Testing

• Ensures safe transfusion by detecting pre-existing antibodies against donor RBCs.

🚩 Pregnancy & Hemolytic Disease of the Newborn (HDN)

• In Rh-negative mothers carrying an Rh-positive baby, maternal antibodies can attack fetal RBCs, leading to fetal anemia or hydrops fetalis.
• Rhogam injection (anti-D immunoglobulin) is given at 28 weeks and postpartum to prevent sensitization.

🚩 Autoimmune Hemolytic Anemia (AIHA)

• Detects antibodies attacking self-RBCs, leading to hemolysis.
• Associated conditions: Lupus, infections, lymphomas.

---

5. Treatment & Management

✔️ For Blood Transfusion Patients:

• Only compatible blood units are selected to prevent hemolysis.
• Patients with significant antibodies may require special antigen-matched RBCs.

✔️ For Pregnancy & HDN Prevention:

• If ICT is positive with low titre → Regular monitoring (every 4 weeks).
• If ICT titre rises (>1:32) → Fetal Doppler ultrasounds & possible intrauterine transfusions.
• Rh-negative mothers receive Rhogam prophylaxis to prevent anti-D antibody formation.

✔️ For Autoimmune Hemolytic Anemia (AIHA):

• Corticosteroids, Immunosuppressants, or Rituximab to reduce antibody production.
• Blood transfusions (if severe anemia is present).

---

Conclusion

The Indirect Coombs Test (ICT Titre) detects antibodies against RBCs, crucial in pregnancy, blood transfusions, and autoimmune hemolytic anemia. A high titre indicates a higher risk for complications, requiring close monitoring and intervention.